Published in Biochemistry on November 04, 1986
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem J (1987) 3.74
A glycophospholipid membrane anchor acts as an apical targeting signal in polarized epithelial cells. J Cell Biol (1989) 3.56
Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. Proc Natl Acad Sci U S A (1988) 3.19
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of complement-regulatory proteins. J Exp Med (1988) 2.75
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Biogenetic pathways of plasma membrane proteins in Caco-2, a human intestinal epithelial cell line. J Cell Biol (1990) 2.02
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 2.01
Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. J Virol (1999) 1.96
Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med (1991) 1.90
Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology (2001) 1.79
Analysis of the signal for attachment of a glycophospholipid membrane anchor. J Cell Biol (1989) 1.77
Identification of an endogenous membrane anchor-cleaving enzyme for group A streptococcal M protein. Its implication for the attachment of surface proteins in gram-positive bacteria. J Exp Med (1989) 1.77
Renal dipeptidase is one of the membrane proteins released by phosphatidylinositol-specific phospholipase C. Biochem J (1987) 1.50
The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J Virol (1996) 1.49
Entry of herpes simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or to lipid rafts occurs through acidic endosomes. J Virol (2004) 1.47
Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest (1988) 1.41
Evidence for glycosyl-phosphatidylinositol anchoring of Toxoplasma gondii major surface antigens. Mol Cell Biol (1989) 1.37
Biosynthesis, membrane association, and release of N-CAM-120, a phosphatidylinositol-linked form of the neural cell adhesion molecule. J Cell Biol (1987) 1.36
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
Complex alternative splicing of acetylcholinesterase transcripts in Torpedo electric organ; primary structure of the precursor of the glycolipid-anchored dimeric form. EMBO J (1988) 1.29
Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol (2008) 1.28
Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med (1987) 1.27
Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc Natl Acad Sci U S A (1987) 1.25
Characterization of the phosphatidylinositol-glycan membrane anchor of human placental alkaline phosphatase. Proc Natl Acad Sci U S A (1987) 1.25
Assembly and deacetylation of N-acetylglucosaminyl-plasmanylinositol in normal and affected paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1991) 1.20
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Immunology (1989) 1.17
Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus. J Clin Microbiol (1989) 1.17
Trypanosome variant surface glycoprotein transfer to target membranes: a model for the pathogenesis of trypanosomiasis. Proc Natl Acad Sci U S A (1990) 1.16
A glycosylphosphatidylinositol (GPI)-negative phenotype produced in Leishmania major by GPI phospholipase C from Trypanosoma brucei: topography of two GPI pathways. J Cell Biol (1994) 1.15
A nonfunctional sequence converted to a signal for glycophosphatidylinositol membrane anchor attachment. J Cell Biol (1991) 1.14
Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1988) 1.14
Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3' end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci U S A (1988) 1.13
Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest (1987) 1.13
Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 1.07
Human immunodeficiency virus infection and syncytium formation in HeLa cells expressing glycophospholipid-anchored CD4. J Virol (1991) 1.06
C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem (2011) 1.01
An internally positioned signal can direct attachment of a glycophospholipid membrane anchor. J Cell Biol (1991) 1.01
Formation and remodeling of inositolphosphoceramide during differentiation of Trypanosoma cruzi from trypomastigote to amastigote. Eukaryot Cell (2003) 1.01
COOH-terminal processing of nascent polypeptides by the glycosylphosphatidylinositol transamidase in the presence of hydrazine is governed by the same parameters as glycosylphosphatidylinositol addition. Proc Natl Acad Sci U S A (1996) 1.00
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol (1992) 0.99
Structure/function studies of human decay-accelerating factor. Immunology (2000) 0.98
Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. Protein Sci (2004) 0.98
Mammalian glycophosphatidylinositol anchor transfer to proteins and posttransfer deacylation. Proc Natl Acad Sci U S A (1998) 0.97
Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1992) 0.96
Glycosylphosphatidylinositol-anchor intermediates associate with triton-insoluble membranes in subcellular compartments that include the endoplasmic reticulum. Biochem J (1999) 0.96
Solution structure of a functionally active fragment of decay-accelerating factor. Proc Natl Acad Sci U S A (2003) 0.94
Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci (2008) 0.92
Characterization of the decay-accelerating factor gene promoter region. Proc Natl Acad Sci U S A (1991) 0.91
Evidence that a glycolipid tail anchors antigen 117 to the plasma membrane of Dictyostelium discoideum cells. Proc Natl Acad Sci U S A (1988) 0.91
Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol (1998) 0.89
Polymorphism and proteolytic fragments of granulocyte membrane cofactor protein (MCP, CD46) of complement. Biochem J (1992) 0.89
Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants. J Clin Invest (1991) 0.88
Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes. J Clin Invest (1990) 0.88
Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant (2010) 0.87
Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect Immun (1998) 0.83
In vitro attachment of glycosyl-inositolphospholipid anchor structures to mouse Thy-1 antigen and human decay-accelerating factor. Proc Natl Acad Sci U S A (1989) 0.83
Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Proc Natl Acad Sci U S A (1989) 0.83
Alterations in protein expression and complement resistance of pathogenic Naegleria amoebae. Infect Immun (1992) 0.82
Preferential expression of human Fc gamma RIIIPMN (CD16) in paroxysmal nocturnal hemoglobinuria. Discordant expression of glycosyl phosphatidylinositol-linked proteins. J Clin Invest (1991) 0.82
Expression of glycoprotein gIII-human decay-accelerating factor chimera on the bovine herpesvirus 1 virion via a glycosyl phosphatidylinositol-based membrane anchor. J Virol (1993) 0.82
Altered expression of gangliosides in erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1990) 0.80
Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC). Clin Exp Immunol (1998) 0.79
Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement. Clin Exp Immunol (1991) 0.79
Characterization of homologous restriction factor (HRF20) in human skin and leucocytes. Clin Exp Immunol (1990) 0.78
Acetylcholinesterase from Apis mellifera head. Evidence for amphiphilic and hydrophilic forms characterized by Triton X-114 phase separation. Biochem J (1988) 0.77
Inositolphosphoceramide metabolism in Trypanosoma cruzi as compared with other trypanosomatids. J Eukaryot Microbiol (2011) 0.76
Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res (2016) 0.75
Characterization of [3H]palmitate- and [3H]ethanolamine-labelled proteins in the multicellular parasitic trematode Schistosoma mansoni. Biochem J (1988) 0.75
Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science (2000) 7.99
New techniques for purifying large DNAs and studying their properties and packaging. Cold Spring Harb Symp Quant Biol (1983) 6.35
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Pilus genes of Neisseria gonorrheae: chromosomal organization and DNA sequence. Proc Natl Acad Sci U S A (1984) 5.37
The repertoire of silent pilus genes in Neisseria gonorrhoeae: evidence for gene conversion. Cell (1986) 4.48
Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol (2001) 3.75
Genetic analysis of the Helicobacter pylori vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. Mol Microbiol (1994) 3.47
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Cloning and genetic characterization of a Helicobacter pylori flagellin gene. Mol Microbiol (1992) 2.97
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
Acetylcholinesterase. Adv Enzymol Relat Areas Mol Biol (1975) 2.81
Membrane complement receptors specific for bound fragments of C3. Adv Immunol (1985) 2.80
Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A (1987) 2.62
Improved preparation of lipoteichoic acids. Eur J Biochem (1983) 2.61
A stable shuttle vector system for efficient genetic complementation of Helicobacter pylori strains by transformation and conjugation. Mol Gen Genet (1998) 2.50
Variation and control of protein expression in Neisseria. Annu Rev Microbiol (1990) 2.49
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene (2000) 2.47
Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology (1994) 2.35
Interaction of two variable proteins (PilE and PilC) required for pilus-mediated adherence of Neisseria gonorrhoeae to human epithelial cells. Mol Microbiol (1992) 2.31
Natural transformation competence in Helicobacter pylori is mediated by the basic components of a type IV secretion system. Mol Microbiol (2001) 2.29
MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology (1997) 2.25
Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C. J Biol Chem (1988) 2.18
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Genetic and functional characterization of the alpAB gene locus essential for the adhesion of Helicobacter pylori to human gastric tissue. Mol Microbiol (1999) 2.06
Determination of different cytomegalovirus immunoglobulins (IgG, IgA, IgM) by immunofluorescence. Arch Gesamte Virusforsch (1972) 2.04
Three-dimensional structures of Drosophila melanogaster acetylcholinesterase and of its complexes with two potent inhibitors. Protein Sci (2000) 1.99
Reassortment of pilin genes in Neisseria gonorrhoeae occurs by two distinct mechanisms. Nature (1989) 1.98
A plasmid cloning system utilizing replication and packaging functions of the filamentous bacteriophage fd. Gene (1985) 1.97
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci U S A (1985) 1.87
Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet (1998) 1.87
Structural characterization of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase by fast atom bombardment mass spectrometry. J Biol Chem (1988) 1.79
Acetylcholinesterase of human erythrocytes and neuromuscular junctions: homologies revealed by monoclonal antibodies. Proc Natl Acad Sci U S A (1982) 1.79
Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology (2001) 1.79
Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology (1995) 1.77
Competition for immune complexes by red cells in human blood. J Clin Lab Immunol (1982) 1.74
A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res (1999) 1.73
Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry (1997) 1.71
Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood (1996) 1.70
Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut (2005) 1.62
Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut (2000) 1.62
A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma (2007) 1.58
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia (2007) 1.58
Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant (2005) 1.57
Effective charge on acetylcholinesterase active sites determined from the ionic strength dependence of association rate constants with cationic ligands. Biochemistry (1980) 1.57
Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage. J Immunol (1990) 1.54
Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem (1999) 1.54
Structure of 18S and 14S acetylcholinesterase. Identification of collagen-like subunits that are linked by disulfide bonds to catalytic subunits. Biochemistry (1977) 1.52
Time-dependent loss of surface complement regulatory activity during storage of donor blood. Transfusion (1993) 1.49
Characterization of putative glycoinositol phospholipid anchor precursors in mammalian cells. Localization of phosphoethanolamine. J Biol Chem (1992) 1.49
The role of lipoteichoic acid biosynthesis in membrane lipid metabolism of growing Staphylococcus aureus. Eur J Biochem (1984) 1.48
Metabolite and matrix interference in phenytoin immunoassays. Clin Chem (1996) 1.45
Natural competence for DNA transformation in Helicobacter pylori: identification and genetic characterization of the comB locus. Mol Microbiol (1998) 1.45
Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant (1994) 1.43
Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest (1988) 1.41
Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy (2004) 1.41
Identification of amine components in a glycolipid membrane-binding domain at the C-terminus of human erythrocyte acetylcholinesterase. Biochemistry (1986) 1.41
Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites. J Biol Chem (2001) 1.40
Induction of the proteolytic activity of a membrane protein in Plasmodium falciparum by phosphatidyl inositol-specific phospholipase C. Nature (1988) 1.40
Brain cDNA clone for human cholinesterase. Proc Natl Acad Sci U S A (1987) 1.39
Acetylthiocholine binds to asp74 at the peripheral site of human acetylcholinesterase as the first step in the catalytic pathway. Biochemistry (2000) 1.39
High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol (1997) 1.39
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun (1998) 1.38
Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin. Clin Chem (2001) 1.38
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia (2013) 1.37
Characterization of DNA used to assay sera for anti-DNA antibodies; determination of the specificities of anti-DNA antibodies in SLE and non-SLE rheumatic disease states. J Immunol (1977) 1.36
Cloning and genetic characterization of Helicobacter pylori catalase and construction of a catalase-deficient mutant strain. J Bacteriol (1996) 1.35
Optimized BlaM-transposon shuttle mutagenesis of Helicobacter pylori allows the identification of novel genetic loci involved in bacterial virulence. Mol Microbiol (1996) 1.34
Interaction of Helicobacter pylori with professional phagocytes: role of the cag pathogenicity island and translocation, phosphorylation and processing of CagA. Cell Microbiol (2001) 1.33
Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c. Proc Natl Acad Sci U S A (1982) 1.33
Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine (1998) 1.32
An interim prosthesis for the glossectomy patient. J Prosthet Dent (1987) 1.30
The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med (1987) 1.29
Quantitative simulation of endplate currents at neuromuscular junctions based on the reaction of acetylcholine with acetylcholine receptor and acetylcholinesterase. Biophys J (1979) 1.28
Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J Immunol (1996) 1.27
Isolation and characterization of acetylcholinesterase from Drosophila. J Biol Chem (1987) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant (2009) 1.27
Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26
Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. J Biol Chem (1972) 1.26
Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. J Pathol (2008) 1.26
Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells. Clin Exp Immunol (1982) 1.26
Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc Natl Acad Sci U S A (1987) 1.25
Cloning of the Helicobacter pylori recA gene and functional characterization of its product. Mol Gen Genet (1995) 1.25
Encoding of movement time by populations of cerebellar Purkinje cells. Nature (2000) 1.24
Analysis of dicarboxylic acids by tandem mass spectrometry. High-throughput quantitative measurement of methylmalonic acid in serum, plasma, and urine. Clin Chem (2001) 1.24
Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med (1984) 1.23
Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. Biochemistry (1998) 1.21
Assembly and deacetylation of N-acetylglucosaminyl-plasmanylinositol in normal and affected paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1991) 1.20
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res (2008) 1.19